CHUNGDO PHARM. CO. LTD. FDA Warning (2017)
Compiled by the Supplement Safety Data Team | Sourced from Official FDA Records on July 21, 2017
Executive Summary
The FDA issued a warning letter to CHUNGDO PHARM. CO. LTD. on July 21, 2017 citing regulatory violations. The letter was issued by the FDA.
Detailed Analysis
False Claims and Regulatory Violations
The FDA identified regulatory violations in CHUNGDO PHARM. CO. LTD.'s operations or product claims.
Potential Health Risks
Shon KimPresidentChungDo Pharm. Co.LTD.202 HI-TECH VENTURE TOWN198-53 HUPEONG-DONGCHUNCHEONJUL z l 2onKorea, Republic of (South) 200-160
Donald J. St. PierreActing Deputy Director forPatient Safety and Product QualityOffice of In Vitro Diagnosticsand Radiological HealthCenter for Devices and Radiological Health
Regulatory Context
The Food and Drug Administration (FDA) has completed an evaluation of your firm's corrective actions in response to our Warning Letter dated July 30, 2013. Based on our evaluation, it appears that your firm has adequately addressed the violations contained in this Warning Letter.
This letter does not relieve your firm from the responsibility of taking all necessary steps to assure sustained compliance with the Federal Food, Drug, and Cosmetic Act and its implementing regulations. The FDA expects your firm to maintain compliance and this letter will not preclude any future regulatory action should violations be observed during a subsequent inspection or through other means.
Key Entities Identified
Frequently Asked Questions
- What did the FDA find wrong with CHUNGDO PHARM. CO. LTD.?
- The FDA issued a warning letter citing regulatory violations related to their products or manufacturing practices.
- Are CHUNGDO PHARM. CO. LTD. products safe to use?
- Based on the FDA's findings, consumers should exercise caution. The company was found to have regulatory issues that may affect product safety.
- What should I do if I've used CHUNGDO PHARM. CO. LTD. products?
- If you have used products from CHUNGDO PHARM. CO. LTD. and experience any adverse effects, contact your healthcare provider immediately. You can also report adverse events to the FDA's MedWatch program.
Source Document
This report is based on an official FDA warning letter. The original document is a public record.
View Original FDA Warning Letter